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Introduction: The liver metastases of colorectal cancer (CRC) can be surgically resected in selected cases with 
continuously improving results. Matrix metalloproteinases (MMPs) contribute to cancer invasion by 
degrading extracellular matrix, and elevated levels of MMP-2, MMP-8, and MMP-9 have been detected in 
several malignancies. Myeloperoxidase (MPO) is a mediator of tissue damage that can oxidatively activate 
latent MMPs. We evaluated the prognostic value of MMP-2, MMP-8, and MMP-9 in tissue samples of primary 
tumors and liver metastases and the pre- and postoperative serum levels of MMP-8, MMP-9, and MPO in 
CRC patients undergoing liver resection.  
Methods: Tissue and serum samples were obtained from 111 patients, who had their primary colorectal 
tumors and liver metastases operated on at the Helsinki University Hospital between 1988 and 2007. Tissue 
expression of MMP-2, MMP-8, and MMP-9 in primary tumors and liver metastases was evaluated by 
immunohistochemistry. Pre- and postoperative serum concentrations of MMP-8, MMP-9, and MPO were 
determined using a time-resolved immunofluorometric assay (IFMA) or commercially available enzyme-
linked immunosorbent assay (ELISA) kits. Clinical data were retrieved from patient records and the Central 
Statistical Office of Finland. Associations with disease-free survival (DFS) and overall survival (OS) were 
estimated using the Cox regression analysis and the Kaplan-Meier method.  
Results: High expression of MMP-9 in colorectal tumor tissue associated with better DFS (P=0.010), and high 
preoperative MPO in serum with improved DFS and OS (P<0.001 and P=0.014, respectively). The prognostic 
significance varied according to gender, age, and the synchronicity of the liver metastases.  
Conclusion: Low preoperative MPO in serum might identify the patients at a high risk of recurrence and death 
after resection of colorectal liver metastases. High expression of MMP-9 in colorectal tumor tissue and 
elevated preoperative MPO in serum indicate improved prognosis. The use of these biomarkers should be 





Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide [1], and the factors affecting 
the course of the disease and prognosis are under continuous investigation. Treatment of stage IV disease 
has improved markedly in the last decades, but it still leads to death in almost 90% of cases [2]. Up to 75% of 
the patients with metastatic disease develop liver metastases [3], and the only curative treatment option is 
surgical resection. Only 10–20% of the liver metastases are operable at the time of diagnosis, but due to 
improved ongological treatment, up to 15% of the initially non-resectable metastases can be converted to 
resectable [4, 5]. However, more than half of the patients develop recurrence after liver resection [6].  
The invasion of the primary tumor into the adjacent tissues is a critical step in cancer metastasis. Invasion 
requires remodeling and degradation of the extracellular matrix (ECM), in which proteolytic enzymes 
(cysteine-, serine-, aspartic-, and metalloproteinases) exert a significant role. Matrix metalloproteinases 
(MMPs) are a family of zinc-dependent genetically distinct but structurally related endopeptidases, which 
are able to degrade almost all extracellular matrix proteins, activate and process bioactive non-matrix 
biomolecules including growth factors and cytokines, and promote immune responses and angiogenesis [7]. 
MMP-2 and MMP-9 belong to the subgroup of gelatinases, and MMP-8 (collagenase-2) to that of 
collagenases. The activity of MMPs is controlled by tissue inhibitors of metalloproteinases (TIMPs), especially 
TIMP-1 [8, 9]. In addition, tumor-associated trypsin inhibitor (TATI) can inhibit the action of trypsin-2, and 
thus, the activation of collagenolytic latent MMPs [10]. MMPs are upregulated in several different 
inflammatory processes as well as in cancer, and their role can be either proinflammatory or anti-
inflammatory depending on the condition and its stage or phase [11]. It is known that tumor development 
triggers inflammation, but the role of MMPs in regulating the inflammatory processes is yet unestablished.  
Overexpression of MMP-2 and MMP-9 in tumor tissue has been associated with poor prognosis in recurrent 
glioma [12]. MMP-2 has indicated poor prognosis also in colorectal cancer [13] and gastric cancer [14, 15]. 
The role of MMP-9 has been controversial, as high tumoral expression has been shown to indicate shortened 
survival in head and neck cancer [16], in gastric cancer in one study [17], and in primary colorectal cancer 
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[18-20], but it has also been associated with better survival in Dukes’ B colorectal cancer [21] and in 
extrahepatic bile duct cancer [22].  
MMP-8 expression in tumor tissue has either not been prognostic or it has been variable [23]. However, there 
is evidence that MMP-8 prevents metastasis through modulation of tumor cell adhesion and invasion [24]. It 
has been shown to protect against the development of skin tumors [25] as well as lymph node metastasis in 
breast cancer [24], and in squamous cell tongue cancer, high expression in cancer cells has been associated 
with improved survival [26].  
Elevated levels of MMP-2, MMP-8, and MMP-9 in serum have been observed in several different cancers. 
Elevated serum concentrations of MMP-8 have associated with worse prognosis in colorectal cancer [27-29], 
hepatocellular cancer [30], and melanoma [31]. Interestingly, in the study by Laitinen et al. [32], both high 
and low serum levels of MMP-8 associated with worse survival in gastric cancer. It has been suggested that 
the serum levels of MMP-2 and MMP-9 might be used for identifying the patients at a high risk of recurrence 
in CRC [33], and MMP-9/TIMP-1 ratio has been prognostic in hepatocellular cancer [30], but otherwise their 
significance is yet unclear.  
Myeloperoxidase (MPO) is a heme-containing peroxidase that is expressed in neutrophils and monocytes. It 
is overexpressed in inflammatory diseases, and it acts as a mediator of microbial defense and tissue damage 
[34]. MPO is thought to contribute to pathogenesis [35], but on the other hand, it is needed for the defensive 
immune responses [36]. It catalyzes the production of hypochlorous acid (HOCl), which leads to reactions 
that generate reactive oxygen intermediates such as chloramines and free radicals [37, 38]. These products 
can attack extracellular tissues and be pathogenic [39]. MPO also activates proMMP-8 and -9 [40], and it has 
been shown that  it regulates the activity of matrix MMP-7 in vitro [41]. On the other hand, it can oxidatively 
inactivate pathogenic microbes and TIMP-1 [42].  
High tumor infiltration of MPO-expressing cells has been associated with significantly improved prognosis in 
colorectal cancer and breast cancer [43, 44]. The prognostic significance of serum MPO in cancer remains to 
be investigated, even though high serum concentrations have been associated with negative lymphovascular 
invasion in breast cancer [45].  
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In this study we evaluated whether the tissue expression of MMP-2, MMP-8, and MMP-9 in both primary 
colorectal tumors and liver metastases or the serum concentrations of MMP-8, MMP-9, and MPO associate 
with prognosis in CRC patients undergoing resection for liver metastases. Their prognostic significance was 
studied in the whole patient cohort and in specified subgroups. The aim was to assess whether these 





Materials and Methods 
Patients 
This study included 111 patients that had both their primary colorectal tumors and liver metastases operated 
on at the Helsinki University Hospital area between the years 1988 and 2007. The primary colorectal tumors 
were operated between 1988 and 2007, and the liver metastases between 1997 and 2007. Tissue samples of 
both primary tumors and liver metastases were obtainable from 60 patients, samples of primary tumor only 
from 21 patients, and samples from liver metastases only from 30 patients. The serum samples were available 
from all patients (Figure 1). The liver metastases were considered synchronous, if they were diagnosed at 
the same time or within 6 months after the operation on the primary tumor, and as metachronous, if they 
were diagnosed later. Clinical data were retrieved from patient records, and information about the dates of 
death was obtained from the Central Statistical Office of Finland (TK-53-1004-9).  
The study was approved by the Ethics Committee of the Helsinki University Hospital (IRB99/07/01, 
HUS531/E6/01, HUS460/E6/05, HUS323/13/3/2008, HUS242/13/03/02/2011, and HUS 226/E6/06, 
extension TMK02 §66 17.4.2013). Collection and analysis of tissue and blood samples were approved by the 
National Supervisory Authority for Welfare and Health (STM Dno 4858/04/047/08 and Valvira Dnro 
10041/06.01.03.01/2012).  
 
Preparation of tissue microarray samples 
Formalin-fixed and paraffin-embedded tissue samples were obtained from the Department of Pathology of 
the Helsinki University Hospital. Representative tumor areas and healthy tissue areas were marked on 
immunohistochemically stained slides with the help of an experienced pathologist (JH). Six punches (1000 
µm in diameter) were taken from each sample’s tumor area, from the invasion front area when possible. The 
punches were taken with a semiautomatic tissue microarray instrument (TMA) (Beecher Instruments, Silver 
Spring, MD) and mounted on TMA paraffin blocks. Two series of blocks were constructed, each containing 3 




Immunohistochemistry of MMP-2, MMP-8, and MMP-9 
TMA blocks were cut into 4-µm-thick sections for immunohistochemistry. Sections were deparaffinized in 
xylene and then rehydrated through a graded alcohol series. For antigen retrieval, the samples were heated 
in Tris-ethylenediaminetetraacetic acid (EDTA) (pH 9) (MMP-2 and MMP-8) or in Tris–HCl (pH 8.5) buffer 
(MMP-9) for 20 minutes at 98°C in the PreTreatment module (Agilent Dako, Lab Vision Corp., Fremont, CA, 
USA). After inactivation of endogenous peroxidases, the sections were first incubated with a mouse 
monoclonal anti-MMP-2 antibody (Clone CA-4001; Lab Vision Corp., Fremont, CA, USA) diluted at 1:50 
overnight, with a polyclonal MMP-8 antibody [46] diluted at 1:400 overnight, or with a mouse monoclonal 
anti-MMP-9 antibody (MS-817-PO; NeoMarkers, Fremont, CA, USA) diluted at 1:1500 for one hour using the 
Dako REAL Antibody Diluent S2022 (Dako), and then with the secondary antibody (Dako Real ENV 
rabbit/mouse HRP antibody) for 30 minutes. The sections were subsequently visualized with Dako Real ENV 
Dab chromogen kept on glass for 10 minutes and counterstained with Dako Mayer’s Hematoxylin S3309. 
They were dehydrated through a graded series of water, ethanol, and xylene, and finally mounted using 
Pertex® Histolab mounting medium. The staining process was performed with the Lab Vision Autostainer 480 
(LabVision Corp., Fremont, CA, USA).  
 
Scoring 
The immunohistochemically stained tumor samples were scored by two independent researchers (RP and 
JH) without knowledge of the patients’ clinical outcome. In case of different scoring results, the samples were 
re-evaluated and a consensus score determined. Spots without cancer cells or with too few cells for adequate 
estimating were excluded.  
The scoring of MMP-2 was based on the intensity of cytoplasmic staining in tumor cells as follows: 0: no 
positivity in any cancer cells; 1: mild staining in all or some cancer cells; 2: moderate staining in most cancer 
cells; and 3: strong staining in all cancer cells (Figure 2).  
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The scoring of MMP-8 was based on the amount of stained inflammatory cells (granulocytes) in immediate 
proximity to the tumor cells, and the scoring was defined as follows: 0: no staining or only one stained 
granulocyte; 1: some stained granulocytes; 2: several stained granulocytes; and 3: abundantly of stained 
granulocytes (Figure 2).  
The scoring of MMP-9 was based on the intensity of granular cytoplasmic staining in the tumor cells as 
follows: 0: no staining; 1: scattered granules in some cancer cells; 2: granules in all or some cancer cells; and 
3: several granules in all cancer cells (Figure 2). In liver tissue, no staining or only some granulary staining was 
seen as well as some stained inflammatory cells.  
 
Serum samples 
The serum samples were taken in conjunction with the liver resection, before and approximately 3 months 
after the resection. The median time between preoperative sampling and the liver resection was 14 days 
(interquartile range [IQR] 8–22 days), and the median time between the resection and postoperative 
sampling 92 days (IQR 88–97 days). The samples were stored in -80˚ Celsius until analyzed.  
The serum concentrations of MMP-8 were measured by a time-resolved immunofluorometric assay (IFMA) 
as described previously [47]. The monoclonal MMP-8 specific antibodies 8708 and 8706 (Oy Medix 
Biochemica Ab, Espoo, Finland) were used as a catching and a tracer antibody, respectively. The tracer 
antibody was labeled using europium chelate [48]. The assay buffer contained 20 mM Tris-HCl (pH 7.5), 0.5 
M NaCl, 5 mM CaCl2, 50 μM ZnCl2, 0.5% BSA, 0.05% sodium azide, and 20 mg/l diethylenetriaminepentaacetic 
acid (DTPA). Samples were diluted in assay buffer and incubated for 1 hour followed by incubation for 1 hour 
with the tracer antibody. Enhancement solution was added, and after 5 minutes, fluorescence was measured 
using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland). The specificity of the monoclonal 
antibodies against MMP-8 corresponded to that of polyclonal MMP-8. The interassay coefficient of variation 
(CV) % was 7.3% and the detection limit 0.08 ng/ml. 
The serum concentrations of MMP-9 and MPO were determined using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits according to the manufacturers’ instructions (MMP-9: Amersham 
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BioSciences UK Ltd., Buckinghamshire, UK; MPO: Immundiagnostik AG, Bensheim, Germany). The detection 
limits were 0.6 ng/ml for MMP-9 and 1.6 ng/ml for MPO [49, 50].  
 
Statistical analyses 
Statistical analyses were carried out and survival curves were created using SPSS Statistics 25 (SPSS Inc., 
Chicago, IL, USA). A P-value of less than 0.05 was considered significant, and statistical trend was defined as 
P<0.1. DFS and OS were calculated from the date of liver resection. DFS was defined as time to any recurrence 
of CRC or death of any cause, and OS as time to death of any cause. All patients were censored at the end of 
follow-up. The data cut-off date was January 11th, 2019. 
The correlations between the immunohistochemical expression and serum concentrations were calculated 
with Spearman’s rank correlation test and their associations with clinical parameters with Fisher’s exact test. 
The biomarkers’ distributions in tissue and serum in the specified subgroups of patients were studied using 
Mann-Whitney U test. Survival curves were created with the Kaplan-Meier method, and the differences 
between the groups were assessed using the log-rank test. Univariate survival analyses were performed with 
the Cox proportional hazards model. Serum concentrations of MMP-8, MMP-9, and MPO were included in 
the Cox regression analyses as log2-transformed continuous variables, as they were non-normally distributed. 
Receiver operating characteristic (ROC) curves in relation to 5-year DFS were used for estimating the optimal 
cut-off values for serum MMP-8, MMP-9, and MPO.  
All the subgroups of patients considered to have clinical relevance and containing enough patients for 
statistical reliability were included in the survival analyses. Thus, the tissue expression, serum concentrations, 
and the prognostic value of the biomarkers were evaluated in the following subgroups: gender (male vs. 
female); age at the liver resection (≤65 vs. >65 years); location of the primary tumor (rectum vs. colon); and 







The patient characteristics are shown in Table 1. Altogether 57.7% of the patients were male. The primary 
tumor was located in the rectum in 48 (43.2%) cases and in the colon in 63 (56.7%) cases. Synchronous liver 
metastases were diagnosed in 66 (59.5%) patients. During the follow-up time after liver resection, 80 (70.1%) 
patients experienced recurrence. Of the recurrences, 18 (22.5%) were diagnosed within 3 months after 
resection, 52 (65.0%) within 3 years, and 10 (12.5%) later. The minimum follow-up time after liver resection 
for all living patients was 11.5 years.  
 
Biomarkers in tissue and serum samples 
The scoring results as well as the medians and IQRs of the serum concentrations are shown in Table 2. High 
MMP-2 expression was observed in 71/81 (87.7%) of the primary tumor samples and in 40/88 (45.5%) of the 
liver metastasis samples, and the expression in primary tumors was higher in colon cancer compared to rectal 
cancer (P=0.014). Tissue expression of MMP-8 was high in 43/81 (53.1%) of the primary tumors and in 33/88 
(37.5%) of the liver metastases, and in synchronous disease, the expression in both primary tumors and liver 
metastases was lower than in metachronous disease (P=0.029 and P=0.039, respectively).  
The expression of MMP-9 was high in 30/81 (37.0%) of the primary tumors and in 20/88 (22.7%) of the liver 
metastases. The expression in primary tumors was lower in ≤65-year-old patients compared to older ones 
(P=0.050) and also in synchronous disease compared to metachronous disease (P=0.037).  
It is worth noticing that in patients with low MMP-9 expression in primary tumors, the median time between 
the operation on the primary tumor and the liver resection was 7.9 months (IQR 4.1–14.2), while it was 15.1 
months (IQR 5.4–20.3) in those with high expression, a difference that was statistically significant (P=0.047, 
Mann-Whitney U test). In patients with low MMP-8 expression in primary tumors, the median time between 
the operations was 7.6 months (IQR 3.6–14.5) compared to 12.5 months (IQR 6.2–18.2) in those with high 
expression (P=0.045, Mann-Whitney U test).  
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The serum concentrations of MMP-8, MMP-9, and MPO did not associate with any of the investigated clinical 
parameters, and there were no statistically significant differences in their distributions.  
 
Correlations and associations 
MMP-2 expression in primary colorectal tumors correlated only with that of MMP-8 in primary tumors (rho 
-0.297, P=0.007), and the expression in liver metastases did not show statistically significant correlations. The 
expression of MMP-8 in primary tumors did not correlate with the other biomarkers, but there was an 
association with the type of liver metastases (synchronous/metachronous) (P=0.043, Fisher’s exact test). 
MMP-8 expression in liver metastases correlated with preoperative serum MMP-8 (rho 0.334, P =0.002) and 
serum MPO (rho 0.218, P =0.044), and also with postoperative serum MMP-8 (rho 0.236, P =0.027). Low 
MMP-8 expression in the liver metastases associated with lower serum concentrations of MMP-8 pre- and 
postoperatively (P =0.004 and P =0.005, respectively; Mann-Whitney U test).  
MMP-9 expression in primary tumors correlated with postoperative serum MMP-8 (rho -0.430, P =0.002), 
when only patients with synchronous liver metastases were included, as low tissue expression associated 
with higher serum concentrations (P=0.002; Mann-Whitney U test). Associations with the location of the 
primary tumor and the type of liver metastases (synchronous/metachronous) were also noted (P=0.031 and 
P=0.017, respectively; Fisher’s exact test). MMP-9 expression in liver metastases did not show statistically 
significant correlations.  
Besides the above-mentioned correlations, the serum values of MMP-8, MMP-9, and MPO all correlated with 
each other pre- and postoperatively (rho 0.197–0.701, P<0.001–0.001), as the lower serum concentrations 
associated with lower ones and higher concentrations with higher ones (all: P<0.001; Mann-Whitney U test). 
In addition, pre- and postoperative serum MMP-8 associated with the location of the primary tumor (P=0.034 
and P=0.066, respectively; Fisher’s exact test), and preoperative serum MPO with age (≤ or >65 years at liver 






The disease-free and overall survival of the patients in different clinical subgroups are presented in Table 3.  
The median disease-free survival time in the whole cohort was 1.4 years (IQR 0.6–9.4), and the median overall 
survival time 5.7 years (IQR 2.7–13.4). Disease-free survival was 29.7% (33/111) at 5 years after resection and 
20.7% (23/111) at the end of follow-up. Overall survival was 59.5% (66/111) at 5 years, 36.9% (41/111) at 10 
years, and 30.6% (34/111) at the end of follow-up.  
When compared with the log-rank test, DFS and OS were significantly shorter among elderly patients than 
among younger ones, when the age was >65 years at the time of the operation on the primary tumor (DFS: 
P=0.036; OS: P=0.013) or at the liver resection (DFS: P=0.014; OS: P=0.041). Patients with T3–4 primary 
tumors had worse survival than those with T1–2 tumors (DFS: P=0.015; OS: P=0.006), as did also patients 
with primary N1–2 status compared to N0 status (OS: P=0.011). In addition, having more than two liver 
metastases indicated shorter DFS nearly significantly (P=0.053). Gender, the synchronicity of the liver 
metastases, or perioperative chemotherapy did not associate with survival statistically significantly.  
 
MMP-2, MMP-8, and MMP-9 in tissue samples and survival 
For the survival analyses, the expressions of MMP-2, MMP-8, and MMP-9 in the tumor samples were grouped 
as “low” (score 0–1) and “high” (score 2–3). The results of the univariate Cox regression analyses are shown 
in Table 4, and those attained using the Kaplan-Meier method are presented in the following section. 
The expression of MMP-2 and MMP-8 in either primary colorectal tumors or liver metastases did not 
associate with shorter DFS or OS, when the whole patient cohort was examined. In women, low MMP-2 
expression in liver metastases associated with shorter DFS (P=0.032) and showed tendency towards shorter 
OS (P=0.055), but otherwise MMP-2 was not prognostic in the subgroups. High expression of MMP-8 in liver 
metastases indicated worse survival only in colon cancer (OS: P=0.046).  
High MMP-9 expression in primary colorectal tumors, on the other hand, associated with improved DFS 
(P=0.010) in the whole cohort and also with better OS nearly significantly (P=0.067) (Figure 3). In addition, 
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high expression of MMP-9 in primary tumors indicated improved prognosis more strongly in the specified 
subgroups as follows: in women (DFS: P=0.005 and OS: P=0.014); in colon cancer (DFS: P=0.011; OS: P=0.037);  
and in metachronous disease (DFS: P=0.005; OS: P=0.032) (Table 5). MMP-9 expression in liver metastases 
did not associate with survival.  
 
MMP-8, MMP-9, and MPO in serum samples and survival 
The results of the univariate Cox regression analyses including the serum concentrations as log2-transformed 
continuous variables are shown in Table 4. In the Kaplan-Meier log-rank analyses, we used the cut-off level 
of 218.6 ng/ml for MPO based on the ROC curve analysis, and that of 77.7 ng/ml for MMP-9, as it was the 
mean of the pre- and postoperative medians and close to the cut point provided by the ROC curves. For 
MMP-8, we decided to use the tertiles of the pre- and postoperative values as cut points, as no statistically 
significant cut-off level was found. Thus, the cut-off values were 29.6 and 76.2 ng/ml for preoperative MMP-
8, and 20.8 and 56.1 ng/ml for postoperative MMP-8.  
When the whole patient cohort was studied, both low and high preoperative values of MMP-8 (≤29.6 and 
>76.2 ng/ml) associated with shorter OS (P=0.023) compared to intermediate values and showed tendency 
towards shorter DFS (P=0.087). The same difference was observed more strongly among male patients (OS: 
P=0.026) and in synchronous disease (OS: P=0.051). Preoperatively high MMP-8 (>76.2 ng/ml) associated 
with shorter survival among >65-year-old patients (OS: P=0.005), but not among younger ones, and with 
shorter DFS and OS in colon cancer (DFS: P=0.020; OS: P=0.002), but not in rectal cancer. Postoperatively low 
values of MMP-8 (≤20.8 ng/ml) associated with better prognosis compared to higher values among >65-year-
old patients (OS: P=0.045), in colon cancer (OS: P=0.020), and in synchronous disease (DFS: P=0.020; OS: 
P=0.002), but not in the whole cohort.  
The pre- and postoperative serum concentrations of MMP-9 did not associate with survival in the whole 
cohort, but postoperatively elevated values (>77.7 ng/ml) associated with worse survival among >65-year-
old patients (DFS: P=0.003; OS: P<0.001) (Figure 4).  
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Preoperatively elevated MPO (>218.6 ng/ml) associated with improved DFS (P<0.001) and OS (P=0.014) in 
the whole cohort (Figure 5), and the association was most significant in the following subgroups: women 
(DFS: P=0.001 and OS: P=0.013); ≤65-year-old patients (DFS: P<0.001; OS: P=0.004); and synchronous disease 
(DFS: P=0.001; OS: P=0.005) (Table 5). Concerning postoperatively elevated MPO (>218.6 ng/ml), no 
statistically significant associations were found.  
In addition, we studied the prognostic value of the changes in serum concentrations between pre- and 
postoperative measurements in the whole patient cohort. Neither postoperative increase nor decrease 
associated with survival. We also combined the tissue and serum expressions of MMP-8 and MMP-9 but did 
not find statistically significant associations with DFS or OS. However, it is worth mentioning that all patients 
with preoperatively elevated serum MPO seemed to have improved prognosis independently of the tumoral 
expression of MMP-2, MMP-8 or MMP-9 (Supplementary Table 1).  
 
Associations with neoadjuvant chemotherapy 
In addition to the previously presented results, we estimated the prognostic significance of the biomarkers 
in primary colorectal tumors and preoperative serum in patients who received neoadjuvant chemotherapy 
before liver resection and in those who did not.  
In patients that did not receive neoadjuvant chemotherapy before liver resection (n=40; 36.0%), low MMP-
8 expression in primary tumors associated with significantly worse survival after liver resection compared to 
high expression (DFS: P=0.005 and OS: P=0.097). However, in patients that did receive neoadjuvant 
chemotherapy (n=66; 59.5%), no difference between the patients with either low and those with high MMP-
8 expression was found. The same was noted for MMP-9, as in patients not having received neoadjuvant 
therapy, low expression in primary tumors associated with worse DFS and OS (P=0.006 and P=0.062, 
respectively), but in those who did receive neoadjuvant therapy, no difference between the low and high 
expression groups was found.  
In patients that received neoadjuvant chemotherapy, low preoperative serum levels of MPO associated with 
significantly worse prognosis (DFS: P<0.001 and OS: P=0.020), while the difference between the low and high 
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concentration groups was non-significant in patients that did not receive neoadjuvant treatment (DFS: 
P=0.120; OS: P=0.266). Patients with low and high preoperative MMP-8 in serum also had worse survival 
(DFS: P=0.026; OS: P=0.043) compared to patients with intermediate values, while no difference was found 






In this retrospective study we demonstrated that high expression of MMP-9 in primary colorectal tumors and 
preoperatively elevated MPO in serum indicate improved prognosis in patients undergoing resection for 
colorectal liver metastases. In addition, the serum concentrations of MMP-8 and MMP-9 had some 
prognostic significance, especially in >65-year-old patients, in colon cancer, and in CRC with synchronous liver 
metastases.  
Earlier, Koskensalo et al. found that positive MMP-9 expression in colorectal tumor tissue indicated better 
prognosis in Dukes’ B disease [21], but in their study, the expression of MMP-2 or MMP-8 did not associate 
with prognosis. The results of our study are similar, revealing that high MMP-9 expression in primary tumor 
tissue associates with better DFS and OS also in stage IV disease. It can be speculated that in case the 
expression of MMP-9 is high in the tumor cells, MMP-9 cannot be released into the surrounding extracellular 
matrix and thus, the invasive capability of the tumor is eventually weaker and prognosis better.  
On the other hand, the expression of MMP-9 has also been associated with poor survival [19, 20] in primary 
CRC, which is contradictory to our results. In our study, high MMP-9 expression associated with better 
prognosis specifically in patients with metachronous liver metastases, that is, stage I–III disease at the time 
of the primary operation. Noteworthy, MMP-9 expression in primary tumors was lower in patients with 
synchronous liver metastases compared to metachronous ones, which corresponds to the results of a 
previous study by Takeha et al. [51]. They found that the number of MMP-9-positive cells along colorectal 
tumors’ invasive margin was significantly smaller in patients with liver metastases or with an infiltrating 
growth pattern. In our material, also the tissue expression of MMP-8 in primary tumors and liver metastases 
was lower in synchronous than in metachronous disease, even though the prognostic significance of MMP-8 
was weak. It can be hypothesized that the tumoral expression pattern changes when CRC becomes 
metastatic, and low expression of MMP-9 in primary tumors reflects either already existing or shortly 
developing liver metastases and thus, worse prognosis. The reason for the difference between the prognostic 
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value of tissue MMP-9 in previous studies and ours remains unclear, but the association with improved 
prognosis has now been demonstrated in at least two studies with similar methods.  
In this study, the expression of MMP-2 and MMP-8 in primary tumors did not associate with survival. MMP-
2 has earlier been found prognostic in CRC [13], but it is possible that the significance changes in a metastatic 
setting. Concerning MMP-8, our results did not offer new information in relation to the previous findings.  
We expected that the expression of MMP-2, MMP-8, or MMP-9 in liver metastases would have associated 
with prognosis, but only weak associations were found in some subgroups. It can be speculated that 
preoperative chemotherapy either affects the prognostic significance of MMPs in liver metastases or reflects 
the response to oncological treatment, and it may consequently alter the expression of MMPs and their 
associations with prognosis. In our patient cohort, a significant number of patients, 59.5%, received 
neoadjuvant chemotherapy before liver resection.  
In this respect it is worth mentioning that all the patients in this study were operated before the year 2008, 
and since then, the chemotherapy options have developed considerably. In particular, the use of vascular 
endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors has become 
common. VEGF promotes angiogenesis and, hence, has an important role in tumor invasion. MMP-9 in known 
to mobilize VEGF in ECM, and VEGF has been suggested to be a downstream effector and possibly a substrate 
of MMP-9 [11]. Considering this, it is possible that the prognostic significance of MMPs depends on the type 
of chemotherapy used, and this aspect should be taken into consideration in the following studies.  
Interestingly, the tissue expressions of MMP-2, MMP-8, and MMP-9 in primary colorectal tumors and liver 
metastases did not correlate with each other. In addition, only MMP-8 expression in liver metastases 
correlated with pre- and postoperative serum MMP-8 and with preoperative serum MPO. In synchronous 
disease, MMP-9 expression in primary tumors correlated negatively with postoperative MMP-8 in serum. It 
seems that the prognostic value of MMP-2, MMP-8, and MMP-9 varies between the primary tumors and 
their liver metastases, and only the serum levels of MMP-8 seem to be related to the tissue expression of 
MMP-8 and possibly to that of MMP-9. These findings suggest that serum MMP-8, MMP-9, and MPO may be 
mainly produced by extratumoral tissues.  
18 
 
In serum, both elevated as well as elevated and low values of MMP-8 have been associated with worse 
prognosis in primary colorectal and gastric cancer [28, 32]. We obtained similar results, as both the high and 
low values before liver resection associated with shorter survival. This refers to a dual role of MMP-8 in 
cancer. However, the prognostic significance of serum MMP-8 in metastatic CRC should be further 
investigated in a larger patient cohort to confirm this.  
The association of preoperatively elevated MPO in serum and improved survival after liver resection is in line 
with the previous results obtained in breast cancer [45]. On the other hand, low preoperative MPO 
concentrations indicated significantly impaired prognosis. To the best of our knowledge, there are no 
previously published studies on serum MPO in metastatic CRC. Our results suggest that MPO has protective 
characteristics in cancer, and it is possible that high concentrations signal a stronger immune response 
against cancer metastasis and thus, a better prognosis. This hypothesis is also supported by our finding that 
MPO was prognostic especially in patients with synchronous liver metastases. MPO is known to oxidatively 
activate proMMP-8 and -9 as well as to inactive TIMP-1, and it can be assumed that combining these 
biomarkers would further help estimate the risk of recurrence after liver resection, also in patients with 
metachronous metastases. Unfortunately, we were able to perform only analyses with limited statistical 
power concerning the combined prognostic value of tissue MMP-8 and MMP-9 and serum MPO because of 
the size of the patient cohort.  
In addition, we observed that the prognostic significance of the investigated biomarkers varied according to 
the patients’ clinical characteristics. MMP-8 in liver metastases and serum, MMP-9 in primary tumors, and 
preoperative MPO in serum associated with prognosis especially in colon cancer, although weaker 
associations in rectal cancer were also found. Pre- and postoperative serum MMP-8 as well as postoperative 
serum MMP-9 associated with survival more strongly in >65-year-old patients than in younger ones. 
Preoperative serum MPO, on the other hand, was prognostic especially in ≤65-year-old patients. This may 
relate to the fact that the inflammatory responses change with ageing [52], and the prognostic significance 
of these biomarkers alters correspondingly. It is possible that the cancer-promoting effects of MMP-8 and 
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MMP-9 are more efficiently compensated in younger patients. Our results suggest that age should be taken 
into consideration when adjusting these biomarkers to clinical use.  
It is also worth mentioning that the prognostic significance of MMP-9 expression in primary tumors and that 
of preoperative serum MPO were stronger in women than in men, possibly referring to a connection with 
hormonal regulation. Stimulation of estrogen receptor α (ERα) has been shown to mediate the upregulation 
of MMP-9 [53] and also the activation of the RAS/ERK pathway, which promotes cancer progression [54]. 
Estrogen itself has been suggested to promote tumorigenesis in mouse models [55], and in a study by Pósa 
et al. [56], estrogen deficiency was associated with increased activity of MPO. Our findings refer to a possible 
link between estrogen, MMP-9, and MPO. High levels of MPO may associate with lower estrogen levels in 
some women and thus, a better prognosis. On the other hand, high estrogen levels followed by stimulation 
of estrogen receptors might cause the release of MMP-9 from inside the tumor cells into the extracellular 
matrix – observed as a low expression in the tumor cells – and, consequently, impaired prognosis.  
The results concerning the differences in the biomarkers’ prognostic value in patients that received or did 
not receive neoadjuvant chemotherapy are interesting. They suggest that the patients with low expression 
of MMP-8 and/or MMP-9 in primary colorectal tumors may benefit from neoadjuvant chemotherapy before 
liver resection, while those with high expression may not necessarily need it. Preoperative serum values of 
MPO and possibly MMP-8, on the other hand, may reflect the response to neoadjuvant therapy and thus, 
risk of recurrence and death. These results should, however, be considered with precaution because of the 
quite small number of patients in the subgroups.  
A limitation of this study is the size of the patient cohort, because of which we were not able to evaluate the 
biomarkers’ prognostic significance in all possible subgroups, and the analyses concerning their combined 
prognostic value were mostly cursory. On the other hand, the statistically significant findings most probably 
are reliable, since they were obvious despite of the quite small cohort. The patients’ RAS and BRAF mutation 
status or the microsatellite instability status of the tumors would have given important additional 




The strengths of our study are the long follow-up period as well as the comprehensive and reliable follow-up 
data. The clinical material is unique, as it consists of tumor tissue samples of both primary CRC tumors and 
their liver metastases in addition to serum samples taken before and after liver resection. In the future, it 
would be valuable to evaluate also the expression of MPO and estrogen receptors in tumor tissue samples 
as well as the serum levels of TIMP-1 and estrogen in a larger cohort of patients with metastatic CRC.  
In conclusion, high expression of MMP-9 in colorectal tumor tissue and preoperatively elevated MPO in 
serum associated with improved prognosis in patients undergoing liver resection for colorectal metastases, 
and low expression and low serum concentrations with poor survival. These biomarkers might identify the 
patients at a high risk of recurrence after liver resection and help adjust their treatment accordingly. Gender, 
age, and the synchronicity of the liver metastases seemed to affect the prognostic significance of these 
biomarkers, possibly via immunological and hormonal mechanisms, which should be investigated further. In 
addition, tissue expression of MMP-8 and MMP-9 in primary colorectal tumors may identify the patients that 
benefit from neoadjuvant chemotherapy before liver resection, and preoperative serum MPO and MMP-8 
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Table 1. Patient characteristics. 
Characteristic 
n (%) or  
median (minimum–maximum) 
Gender 
     Male 





     At the operation on the primary tumor 
     At the liver resection 
     >65 years at the primary operation 
     >65 years at the liver resection 
 
62.8 years (35.5–80.4) 




     Rectum 
     Left colon or rectosigmoid junction 





Primary TNM staging 
     T1–2 
     T3–4 
     Missing data 
     N0 
     N1 
     N2 










     Synchronous1 
     Metachronous 
     ≤2 liver metastases 







     R0 (margin histologically free) 
     R1 (histologic neoplastic infiltration) 





Follow-up time for patients alive 
Overall survival for all patients 
5-year disease-free survival 
5-year overall survival 
10-year overall survival 
15.2 years (11.5–20.3) 




Recurrence after liver resection 
     Yes 




Site of recurrence 
     Liver 
     Other 





Neoadjuvant chemotherapy before liver resection 
     Yes 
     No 
     Missing data 
Adjuvant chemotherapy after liver resection 
     Yes 
     No 













Table 2. Tissue expressions of MMP-2, MMP-8, and MMP-9 and serum concentrations of MMP-8, MMP-9, 
and MPO. 
Tissue biomarkers Colorectal tumors (N=81) 
n (%) 
Liver metastases (N=88) 
n (%) 
MMP-2 
     0 
     1 
     2 












     0 
     1 
     2 












     0 
     1 
     2 











Serum biomarkers Preoperative concentrations (N=111), 
median (IQR) 
Postoperative concentrations (N=111), 
median (IQR) 
MMP-8 (ng/ml) 48.3 (22.9–96.5) 33.2 (16.8–86.8) 
MMP-9 (ng/ml) 79.6 (50.8–111.0) 75.9 (39.8–114.5) 






Table 3. Disease-free survival and overall survival in different subgroups of patients. P-values from log-rank 
test in relation to overall DFS and OS. 
Clinical variable  
N=111 
n (%) 
Disease-free survival Overall survival 
5-year DFS 
n (%) 
P-value 10-year OS 
n (%) 
P-value 
Survival in the whole cohort 111 (100.0) 33 (29.7)  41 (36.9)  
Gender 
     Male 














Age at the primary operation 
     ≤65 years 














Age at the liver resection 
     ≤65 years 














Location of the primary tumor 
     Rectum 
     Left colon or rectosigmoid 
     Right or transversal colon 
     Colon, left and right combined  


























Primary TNM stage 
     T1–2 
     T3–4 
     Missing data 
     N0 
     N1–2 
































     Synchronous 
     Metachronous 
     ≤2 metastases 
     >2 metastases 
     Largest diameter ≤2.0 cm 


































Any neoadjuvant chemotherapy 
before liver resection 
     Yes 
     No 


























Any adjuvant chemotherapy after liver 
resection 
     Yes 
     No 
























Table 4. Results of the univariate Cox regression analysis in relation to disease-free and overall survival. 
Variable Disease-free survival Overall survival 
HR [95% CI] P-value HR [95% CI] P-value 
Gender 
     Male 













Age at primary operation1 










     Rectum 













Primary TNM stage 
     T1–2 
     T3–4 
     N0 






















     Synchronous 
     Metachronous 
Number of metastases1 






















     Minor 














     R0 














before liver resection 
     No 
     Yes 
Adjuvant chemotherapy 
     No 





























MMP-2 in tumor tissue 
     Primary tumors 
        Low (score 0–1) 
        High (score 2–3) 
     Liver metastases 
        Low (score 0–1) 





























MMP-8 in tumor tissue 
     Primary tumors 
        Low (score 0–1) 
        High (score 2–3) 
     Liver metastases 
        Low (score 0–1) 





























MMP-9 in tumor tissue 
     Primary tumors 
        Low (score 0–1) 
        High (score 2–3) 
     Liver metastases 
        Low (score 0–1) 































MMP-8 in serum2 
     Preoperative 













MMP-9 in serum2 
     Preoperative 













MPO in serum2 
     Preoperative 













1 Continuous variable. 















Figure 2. Immunohistochemical staining of MMP-2, MMP-8, and MMP-9 in A) primary colorectal tumors, 
and B) liver metastases. MMP-2: cytoplasmic staining in tumor cells; MMP-8: staining in inflammatory cells; 






Figure 3. The expression of MMP-9 in primary colorectal tumors in relation to A) disease-free survival, and 








Figure 4. Postoperative serum concentrations of MMP-9 in >65-year-old patients in relation to A) disease-















Supplementary Table 1. Preoperative serum concentrations of MPO in relation to 5-year disease-free 
survival and 10-year overall survival in the subgroups of patients with low/high tissue expression of MMP-2, 
MMP-8, and MMP-9. P-values (log-rank test) represent comparison of the MPO levels in the subgroups. MPO: 
low: ≤218.6 ng/ml; high: >218.6 ng/ml; tissue biomarkers: low: score 0–1; high: score 2–3. 
 5-year disease-free survival 10-year overall survival 
n (%)  n (%)  
MPO Low High P-value Low High P-value 
































































Biomarkers in liver metastasis tissue and serum MPO 
MMP-2 
Low 
High 
 
3/30 (10.0) 
1/18 (5.6) 
 
8/17 (47.1) 
10/21 (47.6) 
 
0.012 
0.001 
 
8/30 (26.7) 
3/18 (16.7) 
 
8/17 (47.1) 
13/21 (61.9) 
 
0.220 
0.002 
MMP-8 
Low 
High 
 
5/33 (15.2) 
1/17 (5.9) 
 
10/20 (50.0) 
6/16 (37.5) 
 
0.003 
0.112 
 
9/33 (27.3) 
3/17 (17.6) 
 
12/20 (60.0) 
7/16 (43.8) 
 
0.003 
0.532 
MMP-9 
Low 
High 
 
3/37 (8.1) 
1/11 (9.1) 
 
16/30 (53.3) 
2/8 (25.0) 
 
<0.001 
0.124 
 
6/37 (16.2) 
4/11 (36.4) 
 
16/30 (53.3) 
5/8 (62.5) 
 
0.001 
0.385 
 
 
